Condensed Consolidated Statements of Equity (Deficit) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Total Stockholders’ Equity (Deficit)	Total Stockholders’ Equity (Deficit) Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests in Subsidiaries
Common stock, outstanding, beginning balance (in shares) at Dec. 30, 2018					141,178,000
Stockholders' equity, beginning of period at Dec. 30, 2018	$ (149,886)	$ 9,151	$ (208,696)	$ 9,151	$ 141	$ 2,463,370	$ (187,069)	$ (4,150)	$ (2,480,988)	$ 9,151	$ 58,810
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(104,565)		(89,724)						(89,724)		(14,841)
Other comprehensive income (loss)	99		99					99
Issuance of restricted stock to employees, net of cancellations (in shares)					1,848,000
Issuance of restricted stock to employees, net of cancellations	2		2		$ 2
Stock-based compensation expense	6,628		6,628			6,628
Purchases of treasury stock (in shares)					(633,000)
Purchases of treasury stock	(3,872)		(3,872)		$ (1)		(3,871)
Contributions from noncontrolling interests	20,987										20,987
Common stock, outstanding, ending balance (in shares) at Mar. 31, 2019					142,393,000
Stockholders' equity, end of period at Mar. 31, 2019	(221,456)		(286,412)		$ 142	2,469,998	(190,940)	(4,051)	(2,561,561)		64,956
Common stock, outstanding, beginning balance (in shares) at Dec. 30, 2018					141,178,000
Stockholders' equity, beginning of period at Dec. 30, 2018	(149,886)	$ 9,151	(208,696)	$ 9,151	$ 141	2,463,370	(187,069)	(4,150)	(2,480,988)	$ 9,151	58,810
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	359
Common stock, outstanding, ending balance (in shares) at Sep. 29, 2019					142,577,000
Stockholders' equity, end of period at Sep. 29, 2019	(160,256)		(166,677)		$ 143	2,483,815	(191,725)	(3,791)	(2,455,119)		6,421
Common stock, outstanding, beginning balance (in shares) at Mar. 31, 2019					142,393,000
Stockholders' equity, beginning of period at Mar. 31, 2019	(221,456)		(286,412)		$ 142	2,469,998	(190,940)	(4,051)	(2,561,561)		64,956
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	110,074		121,459						121,459		(11,385)
Other comprehensive income (loss)	166		166					166
Issuance of restricted stock to employees, net of cancellations (in shares)					173,000
Issuance of restricted stock to employees, net of cancellations	1		1		$ 1
Stock-based compensation expense	6,790		6,790			6,790
Purchases of treasury stock (in shares)					(51,000)
Purchases of treasury stock	(494)		(494)				(494)
Contributions from noncontrolling interests	8,590										8,590
Distributions from noncontrolling interests	(316)										(316)
Common stock, outstanding, ending balance (in shares) at Jun. 30, 2019					142,515,000
Stockholders' equity, end of period at Jun. 30, 2019	(96,645)		(158,490)		$ 143	2,476,788	(191,434)	(3,885)	(2,440,102)		61,845
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(19,208)		(15,017)						(15,017)		(4,191)
Other comprehensive income (loss)	94		94					94
Issuance of restricted stock to employees, net of cancellations (in shares)					85,000
Issuance of restricted stock to employees, net of cancellations					$ 0
Stock-based compensation expense	7,027		7,027			7,027
Purchases of treasury stock (in shares)					(23,000)
Purchases of treasury stock	(291)		(291)				(291)
Contributions from noncontrolling interests	1,836										1,836
Distributions from noncontrolling interests	(1,236)										(1,236)
Reduction of non-controlling interests, due to sale of interest in residential lease portfolio	(51,833)										(51,833)
Common stock, outstanding, ending balance (in shares) at Sep. 29, 2019					142,577,000
Stockholders' equity, end of period at Sep. 29, 2019	$ (160,256)		(166,677)		$ 143	2,483,815	(191,725)	(3,791)	(2,455,119)		6,421
Common stock, outstanding, beginning balance (in shares) at Dec. 29, 2019	170,059,000				168,121,000
Stockholders' equity, beginning of period at Dec. 29, 2019	$ 21,499		10,163		$ 168	2,661,819	(192,633)	(9,512)	(2,449,679)		11,336
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(2,138)		(1,431)						(1,431)		(707)
Other comprehensive income (loss)	723		723					723
Issuance of restricted stock to employees, net of cancellations (in shares)					2,452,000
Issuance of restricted stock to employees, net of cancellations	3		3		$ 3
Stock-based compensation expense	6,885		6,885			6,885
Purchases of treasury stock (in shares)					(818,000)
Purchases of treasury stock	(6,911)		(6,911)		$ (1)		(6,910)
Common stock, outstanding, ending balance (in shares) at Mar. 29, 2020					169,755,000
Stockholders' equity, end of period at Mar. 29, 2020	$ 20,061		9,432		$ 170	2,668,704	(199,543)	(8,789)	(2,451,110)		10,629
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201802Member
Common stock, outstanding, beginning balance (in shares) at Dec. 29, 2019	170,059,000				168,121,000
Stockholders' equity, beginning of period at Dec. 29, 2019	$ 21,499		10,163		$ 168	2,661,819	(192,633)	(9,512)	(2,449,679)		11,336
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	$ 175
Common stock, outstanding, ending balance (in shares) at Sep. 27, 2020	170,139,000				170,139,000
Stockholders' equity, end of period at Sep. 27, 2020	$ (7,066)		(10,299)		$ 170	2,679,960	(201,090)	8,070	(2,497,409)		3,233
Common stock, outstanding, beginning balance (in shares) at Mar. 29, 2020					169,755,000
Stockholders' equity, beginning of period at Mar. 29, 2020	20,061		9,432		$ 170	2,668,704	(199,543)	(8,789)	(2,451,110)		10,629
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	18,398		19,378						19,378		(980)
Other comprehensive income (loss)	(1,576)		(1,576)					(1,576)
Issuance of restricted stock to employees, net of cancellations (in shares)					533,000
Issuance of restricted stock to employees, net of cancellations	0		0		$ 0
Stock-based compensation expense	5,675		5,675			5,675
Purchases of treasury stock (in shares)					(229,000)
Purchases of treasury stock	(1,253)		(1,253)				(1,253)
Common stock, outstanding, ending balance (in shares) at Jun. 28, 2020					170,059,000
Stockholders' equity, end of period at Jun. 28, 2020	41,305		31,656		$ 170	2,674,379	(200,796)	(10,365)	(2,431,732)		9,649
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	45,114		44,626						44,626		488
Other comprehensive income (loss)	1,028		1,028					1,028
Issuance of restricted stock to employees, net of cancellations (in shares)					111,000
Issuance of restricted stock to employees, net of cancellations	0		0
Stock-based compensation expense	5,581		5,581			5,581
Purchases of treasury stock (in shares)					(31,000)
Purchases of treasury stock	(294)		(294)				(294)
Issuance of Maxeon Solar green convertible notes	53,040		53,040			53,040
Impact of Maxeon Solar Spin-Off	(152,560)		(145,936)			(53,040)		17,407	(110,303)		(6,624)
Contributions from noncontrolling interests	22										22
Distributions from noncontrolling interests	$ (302)										(302)
Common stock, outstanding, ending balance (in shares) at Sep. 27, 2020	170,139,000				170,139,000
Stockholders' equity, end of period at Sep. 27, 2020	$ (7,066)		$ (10,299)		$ 170	$ 2,679,960	$ (201,090)	$ 8,070	$ (2,497,409)		$ 3,233